血脑屏障通透性指数可预测血肿扩大

2013-10-14 佚名 健康报

首都医科大学附属北京天坛医院神经内科赵性泉教授带领硕士研究生、北大国际医院神经内科医师王玮婧新近完成的一项研究显示,脑出血早期血肿扩大对脑出血预后有重要影响,血脑屏障通透性指数对脑出血早期血肿扩大具有预测作用,其灵敏度和特异性均较高。 脑出血是最严重的脑血管疾病之一,其发病率约占所有脑血管疾病的近两成。现已知,血肿扩大是脑出血预后不良的独立危险因素,但如何快速准确地

首都医科大学附属北京天坛医院神经内科赵性泉教授带领硕士研究生、北大国际医院神经内科医师王玮婧新近完成的一项研究显示,脑出血早期血肿扩大对脑出血预后有重要影响,血脑屏障通透性指数对脑出血早期血肿扩大具有预测作用,其灵敏度和特异性均较高。

脑出血是最严重的脑血管疾病之一,其发病率约占所有脑血管疾病的近两成。现已知,血肿扩大是脑出血预后不良的独立危险因素,但如何快速准确地预测血肿扩大一直是临床研究的难题。过去判断血肿是否扩大主要看强化后的影像血管造影剂是否外渗来定性,此方法多依赖医师的经验判断,而实际应用差异性很大,极易误诊。

赵性泉等选取北京天坛医院近5年接诊的40名发病在6个小时以内的急性脑出血患者作为研究对象,入院时以及在发病24小时时均行颅脑CT检查,确定出血部位,计算对比两次检查的出血量。凡是此时出血量较入院时增加33%以上的视为血肿扩大,并依此分为血肿扩大组和血肿未扩大组。通过计算机断层扫描血管成像,比较入院及发病24小时计算机断层扫描(CT)的血肿体积、测量血肿周围、水肿周围和远隔区域组织的血脑屏障通透性,以此来预测血肿扩大的灵敏度及特异度。

研究结果显示,血肿扩大的发生率为45%,血肿扩大组血肿周围组织血脑屏障通透性指数明显高于未扩大组;血肿周围水肿组织通透性指数越大的患者,其发生血肿扩大的可能性亦越高;血脑屏障通透性指数诊断血肿扩大的预测灵敏度为88.89%,特异度为68.18%。

赵性泉介绍,血脑屏障通透性指数是指患者患侧通透性面积与健侧通透性面积的比值,此方法能够消除患者个体差异的影响,其计算血肿体积较以往研究更加准确。

此研究首次将血脑屏障通透性指数应用于预测脑出血血肿扩大,为临床早发现、早干预及改善患者预后提供了一种较为简便的量化指标。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085636, encodeId=959e2085636c4, content=<a href='/topic/show?id=26dd9492ef1' target=_blank style='color:#2F92EE;'>#通透性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94927, encryptionId=26dd9492ef1, topicName=通透性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Fri May 02 19:46:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709743, encodeId=40541e0974348, content=<a href='/topic/show?id=a329899025a' target=_blank style='color:#2F92EE;'>#血肿扩大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89902, encryptionId=a329899025a, topicName=血肿扩大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b7f31781183, createdName=ms1774076774505970, createdTime=Fri Jun 13 01:46:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262321, encodeId=d67012623210a, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Wed Oct 16 04:46:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394896, encodeId=dd4f139489603, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Wed Oct 16 04:46:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]
    2014-05-02 zhmscau
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085636, encodeId=959e2085636c4, content=<a href='/topic/show?id=26dd9492ef1' target=_blank style='color:#2F92EE;'>#通透性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94927, encryptionId=26dd9492ef1, topicName=通透性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Fri May 02 19:46:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709743, encodeId=40541e0974348, content=<a href='/topic/show?id=a329899025a' target=_blank style='color:#2F92EE;'>#血肿扩大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89902, encryptionId=a329899025a, topicName=血肿扩大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b7f31781183, createdName=ms1774076774505970, createdTime=Fri Jun 13 01:46:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262321, encodeId=d67012623210a, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Wed Oct 16 04:46:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394896, encodeId=dd4f139489603, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Wed Oct 16 04:46:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085636, encodeId=959e2085636c4, content=<a href='/topic/show?id=26dd9492ef1' target=_blank style='color:#2F92EE;'>#通透性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94927, encryptionId=26dd9492ef1, topicName=通透性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Fri May 02 19:46:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709743, encodeId=40541e0974348, content=<a href='/topic/show?id=a329899025a' target=_blank style='color:#2F92EE;'>#血肿扩大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89902, encryptionId=a329899025a, topicName=血肿扩大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b7f31781183, createdName=ms1774076774505970, createdTime=Fri Jun 13 01:46:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262321, encodeId=d67012623210a, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Wed Oct 16 04:46:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394896, encodeId=dd4f139489603, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Wed Oct 16 04:46:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2085636, encodeId=959e2085636c4, content=<a href='/topic/show?id=26dd9492ef1' target=_blank style='color:#2F92EE;'>#通透性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94927, encryptionId=26dd9492ef1, topicName=通透性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Fri May 02 19:46:00 CST 2014, time=2014-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709743, encodeId=40541e0974348, content=<a href='/topic/show?id=a329899025a' target=_blank style='color:#2F92EE;'>#血肿扩大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89902, encryptionId=a329899025a, topicName=血肿扩大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b7f31781183, createdName=ms1774076774505970, createdTime=Fri Jun 13 01:46:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262321, encodeId=d67012623210a, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Wed Oct 16 04:46:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394896, encodeId=dd4f139489603, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Wed Oct 16 04:46:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]

相关资讯

PNAS:新型双功能衔接蛋白或可治疗脑瘤

       近日,美国杜克大学医学院研究人员研发出一种人工蛋白质,通过小鼠试验,该蛋白质可有效杀灭脑瘤细胞同时不对其他脑组织造成损害,此外,该人工蛋白可被用于临床,增强人体自然免疫系统功能来对抗癌症,从而解决了其他免疫疗法的有效性受到限制的问题。   这种人工蛋白有两条臂,一条臂只绑定于肿瘤细胞,另一条则紧紧抓住T细胞,这样可刺激T细胞对肿瘤细胞发起攻击。在参试的8只患有脑瘤的小鼠中,有6只

ME:“分子特洛伊木马”可帮助药物透过血脑屏障

脑部血管内皮细胞之间的相互连接非常紧密,这是制药产业在研发神经系统疾病新药过程中难以逾越的障碍之一。血脑屏障在阻止对具有潜在危害的有毒物质进入脑内的同时也将小分子或大分子药物拒之脑外。 哥伦比亚大学大脑研究所的WilliamPartridge博士开发出了一种能使药物分子穿过血脑屏障的方法,此项研究成果引起了伯林格因格海姆风投基金、赛尔公司、泰克达风投有限公司和三井全球投资有限公司的投资兴趣,其中

Neural Regen Res:修饰脂质体可跨越血脊髓屏障及血脑屏障

研究表明,单纯脂质体通过静脉注射后,仅有少量可以穿过血脑屏障。跨膜肽修饰的脂质体可以携带药物治疗颅内感染,同时经聚乙二醇修饰增加了其稳定性,并可以更长时间的存在于体循环中。一项关于“Transactivating-transduction protein-polyethylene glycol modified liposomes traverse the blood-spinal cord an

PNAS:恢复血脑屏障的完整性

一项研究发现,恢复血脑屏障的完整性可能有助于减缓并逆转诸如多发性硬化、阿兹海默病和帕金森病的发展。几种退行性脑病能削弱血脑屏障——这是把血流和中枢神经系统的液体分隔开来的人体天然机制——因此也就让不适宜的分子进入了大脑,产生了灾难性的后果。Egle Solito及其同事确定了称为Annexin A1 (ANXA1)的基因产物调控着大脑内皮细胞的这种屏障的完整性,该基因就是在大脑内皮细胞表达的。这组

JCI:血脑屏障的免疫交换或助力多发性硬化症研究

2012年11月21日 讯 /生物谷BIOON/ --近日,刊登在国际杂志Journal of Clinical Investigation上的一篇研究报告中,来自加州大学的研究者通过获取一些多发性硬化病人多的DNA序列并进行研究,揭示了一种“免疫交换”机制的存在,这种机制可以使得致病细胞在大脑内外互相移动。 从脑脊髓液和血样中获取的细胞名为B细胞,其可以帮助机体清理来自外部的机体感染。当前认为